Imagene's core product is a molecular and micro-environment intelligence platform that delivers real-time biomarker reports using only digitized biopsy images. Its deep-learning algorithms classify patterns invisible to the human eye and translate spatial, genomic, and proteomic signals into actionable molecular analysis, reducing biomarker-detection time from several weeks to about two minutes. The company says this enables better patient stratification for clinical trials and discovery of novel drug targets, and aims to broaden access to precision medicine so more patients receive the most effective treatments. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide to drive therapeutic decision-making and accelerate drug development. The platform is currently used for research purposes and is subject to regulatory clearances in applicable markets. Imagene was founded in 2020 and maintains a multidisciplinary team of science, clinical, and deep-learning experts; it recently raised capital to expand its operations and technology deployment.

Total raised

$22M

Funding rounds

2

Latest round

Seed

Latest activity

May 2022